reports
Vivid Seats Renews National Make-A-Wish® Partnership to Grant Live Eve...
Vivid Seats Renews National Make-A-Wish® Partnership to Grant Live Event Experiences Celebrates World Wish Month™ with Donation Match CHICAGO, April 25, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: SEAT), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, today announced it has renewed its partnership with Make-A-Wish, a global organization responsible for creating life-changing wishes for children with critical illnesses. In celebration of World Wish Month™, Vivid Seats is m...
One Stop Systems to Report First Quarter 2024 Financial Results
One Stop Systems to Report First Quarter 2024 Financial Results Conference Call to be Held Thursday, May 9, 2024, at 5:00 p.m. ET ESCONDIDO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. (“OSS” or the "Company") (Nasdaq: OSS), a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML) and sensor processing at the edge, announced today that the Company will release its first quarter 2024 financial results after the market closes on Thursday, May 9, 2024. A webcast and conference call will be held that same day at 5:00 p.m. ET t...
Airship AI Announces $2.35 Million Sole-Source Contract Award within t...
Airship AI Announces $2.35 Million Sole-Source Contract Award within the Department of Justice for Outpost AI Edge Appliances Previously Announced Award for Airship AI’s Acropolis Enterprise Video and Data Management Platform in the FedRAMP Environment Successfully Developed into Additional DOJ Award for Outpost AI REDMOND, Wash., April 25, 2024 (GLOBE NEWSWIRE) -- Airship AI Holdings, Inc. (NASDAQ: AISP) (“Airship AI” or the “Company”), a leader in AI-driven video, sensor, and data management surveillance solutions, has been awarded a multi-million dollar contract to an agency within t...
Journey Medical Corporation to Present at the Planet MicroCap Showcase...
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, announced today that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Planet MicroCap...
Calian Wins $23 Million Contract for New Military Medical Training Pro...
Calian Wins $23 Million Contract for New Military Medical Training Program with the Canadian Armed Forces OTTAWA, April 25, 2024 (GLOBE NEWSWIRE) -- Calian Group Ltd. (TSX: CGY), a provider of diverse and innovative solutions in healthcare, communications, learning and cybersecurity, has been awarded a significant contract by the Canadian Armed Forces' Canadian Forces Health Services Group (CFHSG). Valued at $17 million for three years with an option to extend for a fourth year, potentially increasing the total value to $23 million, this contract highlights Calian’s commitment to leveragi...
Star Equity Holdings Announces its KBS Builders Business Unit Closed a...
Star Equity Holdings Announces its KBS Builders Business Unit Closed a $4 Million Revolving Line of Credit with KeyBank OLD GREENWICH, Conn., April 25, 2024 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (Nasdaq: STRR; STRRP) (“Star” or the “Company”), a diversified holding company, announced today that its KBS Builders, Inc. (“KBS”) business unit has closed a $4 million revolving line of credit (“LOC”) with KeyBank National Association (“KeyBank”). KBS intends to use the LOC to meet its working capital requirements and execute its business plan. The closing of this LOC provides both KBS ...
Kuehne + Nagel International AG: 1 director
A director at Kuehne + Nagel International AG bought 4,100 shares at 243.504CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
Ancom Nylex Berhad: 2 directors
Two Directors at Ancom Nylex Berhad bought/sold 4,000,000 shares at 1.040MYR. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
- ABGSC Construct. & Real Estate Research
- Fredrik Stensved
- Markus Henriksson
- Viktor Stenlöf
Hanmi Financial Declares Cash Dividend of $0.25 per share and Announce...
Hanmi Financial Declares Cash Dividend of $0.25 per share and Announces New Share Repurchase Authorization LOS ANGELES, April 25, 2024 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation (NASDAQ: HAFC, or “Hanmi”), the parent company of Hanmi Bank (the “Bank”), today announced that its Board of Directors declared a cash dividend on its common stock for the 2024 second quarter of $0.25 per share. The dividend will be paid on May 22, 2024, to stockholders of record as of the close of business on May 6, 2024. In addition, the Board of Directors today approved a new stock repurchase program. Und...
Ladder Capital Corp Reports Results for the Quarter Ended March 31, 20...
NEW YORK--(BUSINESS WIRE)-- Ladder Capital Corp (NYSE: LADR) (“we,” “our,” “Ladder,” or the “Company”) today announced operating results for the quarter ended March 31, 2024. GAAP income before taxes for the three months ended March 31, 2024 was $18.4 million, and diluted earnings per share (“EPS”) was $0.13. Distributable earnings was $42.3 million, or $0.33 of distributable EPS. “We are pleased with Ladder’s first quarter results, as we continue to navigate through the current credit cycle, increased global tensions, heightened market volatility, and persistently high interest rates. With ...
Phunware Sets First Quarter 2024 Earnings Call for Thursday, May 9, 20...
Phunware Sets First Quarter 2024 Earnings Call for Thursday, May 9, 2024 at 4:30 p.m. ET AUSTIN, Texas, April 25, 2024 (GLOBE NEWSWIRE) -- (“Phunware” or “the Company”), the leading provider of patented wayfinding and mobile engagement solutions that enable brands to engage, manage and monetize anyone anywhere, will hold a conference call on Thursday, May 9, 2024, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results for the first quarter ended March 31, 2024. Financial results will be issued in a press release prior to the call. Phunware management will ho...
Hyliion and BayoTech Partner to Provide Sustainable Power with Hydroge...
AUSTIN, Texas--(BUSINESS WIRE)-- (NYSE: HYLN) (“Hyliion”), a developer of sustainable electricity-producing technology, and , an innovator in hydrogen production, transportation and storage solutions, today announced the signing of a Partnership Agreement (Agreement) aimed at leveraging the expertise of both companies to offer comprehensive power solutions to their existing and future customers. The partnership will allow the companies to introduce their innovative solutions to each other's customer bases. Recognizing the complementary nature of their products and customer needs, the compan...
Supremex Announces Date of Its 2024 First Quarter Results Conference C...
Supremex Announces Date of Its 2024 First Quarter Results Conference Call and Annual Meeting of Shareholders MONTREAL, April 25, 2024 (GLOBE NEWSWIRE) -- Supremex Inc. (“Supremex” or the “Company”) (TSX: SXP), a leading North American manufacturer and marketer of envelopes and a growing provider of paper-based packaging solutions, will release its results for the first quarter ended March 31, 2024, after markets close Wednesday, May 8, 2024. A conference call to discuss these results will be held on Thursday, May 9, 2024, at 8:30 a.m. (Eastern Time). Conference Call: A live broadcas...
Sportradar to Release First Quarter Financial Results on May 15, 2024
Sportradar to Release First Quarter Financial Results on May 15, 2024 ST. GALLEN, Switzerland, April 25, 2024 (GLOBE NEWSWIRE) -- Sportradar Group AG (NASDAQ: SRAD) (“Sportradar”) will release its financial and operating results for the first quarter ended March 31, 2024 on Wednesday, May 15, 2024. Sportradar will also host an earnings call via webcast to discuss the results at 8:30 a.m. ET on Wednesday, May 15, 2024. Those wishing to either listen to, or participate in, the earnings webcast can do so by accessing Sportradar’s Investor Relations website at . Additionally, a replay will b...
Elicio Therapeutics to Present New Preliminary Data from the Ongoing A...
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will be sharing new preliminary data from the ongoing AMPLIFY-7P Phase 1/2 study in a poster presentation at the 2024 American Society of Clinical Onco...
Stronghold Announces Preliminary First Quarter 2024 Results
Stronghold Announces Preliminary First Quarter 2024 Results NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: SDIG) (“Stronghold”, or the “Company”) today reported preliminary unaudited financial results for the first quarter ended March 31, 2024: First Quarter 2024 Financial Performance Stronghold generated an estimated $27.5 million of revenue, an estimated $5.8 million of GAAP Net Income, and an estimated $8.7 million of adjusted EBITDA1 during the first quarter of 2024. Revenue comprised an estimated $26.7 million from cryptocurrency mining, an estimated $0.7 million from the s...
Supremex annonce la date de tenue de la téléconférence pour ses résult...
Supremex annonce la date de tenue de la téléconférence pour ses résultats du T1 2024 et de l’assemblée annuelle des actionnaires MONTRÉAL, 25 avr. 2024 (GLOBE NEWSWIRE) -- Supremex inc. (« Supremex » ou la « Société ») (TSX : SXP), un chef de file nord-américain dans la fabrication et la distribution d’enveloppes ainsi qu’un fournisseur de solutions d’emballage en plein essor, dévoilera ses résultats financiers pour le premier trimestre clos le 31 mars 2024, le mercredi 8 mai 2024 après la fermeture des marchés. Une téléconférence sera tenue le jeudi 9 mai 2024, à 8 h 30 (heure de l’Est) ...
Kearny Financial Corp. Announces Third Quarter Fiscal 2024 Results and...
Kearny Financial Corp. Announces Third Quarter Fiscal 2024 Results and Declaration of Cash Dividend FAIRFIELD, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Kearny Financial Corp. (NASDAQ GS: KRNY) (the “Company”), the holding company of Kearny Bank (the “Bank”), reported net income for the quarter ended March 31, 2024 of $7.4 million, or $0.12 per diluted share, compared to a net loss of $13.8 million, or $0.22 per diluted share, for the quarter ended December 31, 2023. The net loss for the quarter ended December 31, 2023 was impacted by various non-recurring items, as previously disclosed. ...
Apollomics Announces Approval of Vebreltinib in China as a First-in-Cl...
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene Apollomics’ partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion gene Approval based on results from a randomized Phase 2/3 trial FOSTER CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant ca...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.